N-(3-imidazol-1-ylpropyl)-2-phenylacetamide | 279236-91-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-imidazol-1-ylpropyl)-2-phenylacetamide
• CAS: 279236-91-8
• 化学式: C₁₄H₁₇N₃O
• 分子量: 243.308
• InChiKey: QTCHOYQEJRIXGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(3-imidazol-1-ylpropyl)-2-phenylacetamide 在 dimethyl sulfide borane 、 盐酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 生成 3-imidazol-1-yl-N-(2-phenylethyl)propan-1-amine
  参考文献：
  名称：

  WO2007/84498

  摘要：

  公开号：
• 作为产物：
  描述：

  1-(3-氨基丙基)咪唑 、 苯乙酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-(3-imidazol-1-ylpropyl)-2-phenylacetamide
  参考文献：
  名称：

  WO2007/84498

  摘要：

  公开号：

文献信息

• Structure-activity and in vivo evaluation of a novel lipoprotein lipase (LPL) activator
  作者：Werner J. Geldenhuys、Joel Caporoso、Thomas C. Leeper、Yoon-Kwang Lee、Li Lin、Altaf S. Darvesh、Prabodh Sadana

  DOI：10.1016/j.bmcl.2016.11.053

  日期：2017.1

  Elevated triglycerides (TG) contribute towards increased risk for cardiovascular disease. Lipoprotein lipase (LPL) is an enzyme that is responsible for the metabolism of core triglycerides of very-low density lipoproteins (VLDL) and chylomicrons in the vasculature. In this study, we explored the structure-activity relationships of our lead compound (C10d) that we have previously identified as an LPL agonist. We found that the cyclopropyl moiety of C10d is not absolutely necessary for LPL activity. Several substitutions were found to result in loss of LPL activity. The compound C10d was also tested in vivo for its lipid lowering activity. Mice were fed a high-fat diet (HFD) for four months, and treated for one week at 10 mg/kg. At this dose, C10d exhibited in vivo biological activity as indicated by lower TG and cholesterol levels as well as reduced body fat content as determined by ECHO-MRI. Furthermore, C10d also reduced the HFD induced fat accumulation in the liver. Our study has provided insights into the structural and functional characteristics of this novel LPL activator. (C) 2016 Elsevier Ltd. All rights reserved.
• Farnesyl protein transferase inhibitors
  申请人：Kelly M. Joseph

  公开号：US20070213340A1

  公开（公告）日：2007-09-13

  Disclosed are compounds of the formula: wherein R 13 represents an imidazole ring; R 14 represents a carbamate, urea, amide or sulfonamide group, and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.
• Novel Inhibitors of Glutaminyl Cyclase
  申请人：Schilling Stephan

  公开号：US20090018087A1

  公开（公告）日：2009-01-15

  The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.
• USE OF GLUTAMINYL CYCLASE INHIBITORS
  申请人：Schilling Stephan

  公开号：US20090068699A1

  公开（公告）日：2009-03-12

  An inhibitor of a glutaminyl peptide cyclotransferase, and use thereof for the treatment and/or prevention of a disease or disorder selected from the group consisting of inflammatory diseases selected from a. neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis, b. chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis, c. fibrosis, e.g. lung fibrosis, liver fibrosis, renal fibrosis, d. cancer, e.g. cancer/hemangioendothelioma proliferation, gastric carcinomas, e. metabolic diseases, e.g. hypertension, f. and other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis. Additionally disclosed are a respective diagnostic method, assay and kit.
• METHODS OF TREATING OR PREVENTING AN INFLAMMATORY DISEASE OR CONDITION USING GLUTAMINYL CYCLASE INHIBITORS
  申请人：Schilling Stephan

  公开号：US20120184518A1

  公开（公告）日：2012-07-19

  Methods for the treatment and/or prevention of an inflammatory disease or disorder through administration of an inhibitor of a glutaminyl peptide cyclotransferase. Inflammatory diseases or disorders treated or prevented by methods disclosed herein include mild cognitive impairment (MCI), rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis, sepsis and peritonitus. Further provided are respective diagnostic methods, assays and kits.